Insider Selling: Medline (NASDAQ:MDLN) Major Shareholder Sells $90,884,814.65 in Stock

October 8, 2026 by InsiderTrades.com

Key Points

Major shareholder Private Ltd GIC sold 2.57 million Medline shares at an average price of $35.35, generating approximately $90.9 million and reducing its position by 11.28% to 20.23 million shares.
GIC has reported several additional large sales, including transactions totaling hundreds of millions of dollars, potentially increasing share supply and weighing on investor sentiment.
Medline shares opened at $35.45, while the company faces product-quality and potential litigation concerns; analysts nevertheless maintain a consensus “Moderate Buy” rating with a $46.88 price target.

Medline (NASDAQ:MDLN - Get Free Report) major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the completion of the transaction, the insider directly owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. The trade was a 11.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Private Ltd Gic also recently made the following trade(s):

On Tuesday, October 6th, Private Ltd Gic sold 7,183,013 shares of Medline stock. The stock was sold at an average price of $35.05, for a total transaction of $251,764,605.65.
On Tuesday, October 6th, Private Ltd Gic sold 2,088,987 shares of Medline stock. The stock was sold at an average price of $35.05, for a total transaction of $73,218,994.35.
On Monday, October 5th, Private Ltd Gic sold 1,688,690 shares of Medline stock. The shares were sold at an average price of $35.78, for a total transaction of $60,421,328.20.
On Friday, October 2nd, Private Ltd Gic sold 7,146,941 shares of Medline stock. The stock was sold at an average price of $34.33, for a total transaction of $245,354,484.53.
On Friday, August 14th, Private Ltd Gic sold 100,000 shares of Medline stock. The stock was sold at an average price of $35.80, for a total value of $3,580,000.00.
On Thursday, August 13th, Private Ltd Gic sold 1,500,000 shares of Medline stock. The shares were sold at an average price of $35.80, for a total value of $53,700,000.00.
On Friday, August 7th, Private Ltd Gic sold 590,284 shares of Medline stock. The shares were sold at an average price of $35.58, for a total value of $21,002,304.72.
On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The shares were sold at an average price of $35.33, for a total value of $9,609,548.02.
On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The stock was sold at an average price of $35.60, for a total value of $70,367,600.80.

Medline Stock Down 0.3%

Shares of Medline stock opened at $35.45 on Thursday. The firm has a market cap of $46.61 billion and a PE ratio of 44.87. The business's 50 day simple moving average is $35.02 and its 200 day simple moving average is $38.49. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33. Medline has a 52-week low of $31.49 and a 52-week high of $50.88.

Medline (NASDAQ:MDLN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.32 by $0.18. The firm had revenue of $7.68 billion for the quarter. On average, analysts predict that Medline will post 1.51 earnings per share for the current fiscal year.

Medline News Roundup

Here are the key news stories impacting Medline this week:

Neutral Sentiment: Medline will release its third-quarter 2026 results before the market opens on November 4, followed by a conference call. The report should provide updates on demand, margins, product-quality issues and the company’s outlook. Medline third-quarter 2026 results announcement
Negative Sentiment: Major shareholder Private Ltd GIC reported several large sales, including 2.57 million shares on October 2, 1.69 million on October 5 and 2.09 million on October 6. The transactions totaled roughly $224.5 million and materially reduced its ownership. The repeated selling may pressure MDLN by increasing share supply and signaling weaker shareholder conviction, although no reason was provided. SEC ownership filing
Negative Sentiment: Several law firms, including Bleichmar Fonti & Auld, Pomerantz, Kaplan Fox and Kirby McInerney, announced investigations into Medline’s disclosures following a sharp stock decline. The notices allege potential securities-law violations related to manufacturing and product-quality statements; they do not establish wrongdoing, but raise risks of litigation costs, regulatory scrutiny and reputational damage. BFA Law Medline investor reminder
Negative Sentiment: Product-quality concerns remain the main fundamental overhang. Investors may be concerned about possible recalls, remediation expenses, operational disruptions and effects on customer relationships until Medline provides more clarity in its upcoming results.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MDLN. Wells Fargo & Company decreased their target price on shares of Medline from $45.00 to $34.00 and set an "equal weight" rating for the company in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft set a $37.00 price target on shares of Medline in a research report on Thursday, August 6th. UBS Group decreased their price objective on Medline from $45.00 to $43.00 and set a "buy" rating for the company in a report on Friday, September 25th. Royal Bank Of Canada lowered their target price on Medline from $53.00 to $46.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Finally, Truist Financial dropped their target price on Medline from $56.00 to $47.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $46.88.

Check Out Our Latest Stock Report on Medline

Hedge Funds Weigh In On Medline

A number of institutional investors have recently added to or reduced their stakes in MDLN. GAMMA Investing LLC increased its stake in shares of Medline by 68.3% during the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company's stock worth $25,000 after purchasing an additional 254 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Medline by 100.0% in the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company's stock valued at $37,000 after purchasing an additional 475 shares during the last quarter. Allworth Financial LP grew its holdings in Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company's stock worth $41,000 after purchasing an additional 487 shares during the period. North Star Investment Management Corp. grew its holdings in Medline by 60.2% during the first quarter. North Star Investment Management Corp. now owns 1,362 shares of the company's stock worth $61,000 after purchasing an additional 512 shares during the period. Finally, Whipplewood Advisors LLC acquired a new position in Medline during the first quarter worth approximately $30,000.

Medline Company Profile

(Get Free Report)

Medline Industries, Inc is a healthcare company that manufactures and distributes medical supplies, clinical products and equipment to hospitals, health systems, physician practices, long-term care facilities, surgery centers and other healthcare providers. Its offerings are designed to support patient care, surgical procedures, infection prevention and healthcare facility operations.

The company's product portfolio includes surgical instruments and supplies, exam gloves and protective apparel, wound care products, patient-care items, respiratory and monitoring equipment, laboratory supplies, durable medical equipment and products for environmental and facility management.